AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously ...

Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...

The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in ...

AstraZeneca's supplemental New Drug Application for Calquence (acalabrutinib) has been granted Priority Review by the US FDA ...

Geekco Technologies Corporation (the "Corporation" or "Geekco") announces that it extends until November 4, 2024 its non-brokered private placement (the "Private Placement") for which, as announced on ...

Shincheonji Church of Jesus, the Temple of the Tabernacle of the Testimony, is currently hosting a series of seminars titled, "2024 Shincheonji's Bible Seminar on Testifying to the Fulfillment of ...

(Alliance News) - AstraZeneca PLC on Thursday said its cancer treatment Calquence obtained priority review by the US Food & Drug Administration for a form of lymphoma.

Emma Operacz is looking for as close to a 100% match as possible for the best odds that her cancer doesn't return.

Accelerating the decline in tobacco smoking globally, by decreasing smoking prevalence from current levels to 5% everywhere, ...

Roche's Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech's programmable T cell-based therapies platform. Genentech is ...

Sep. 10, 2024 — Phase separation, when molecules part like oil and water, works alongside oxygen diffusion to help memristors -- electrical components that store ... Electrically Modulated Light ...